Detection of hepatitis B virus DNA among accepted blood donors in Nanjing, China

Virology Journal

Volumn 7, Issue , 2010, Pages

  Liu, Yong ^a   Li, Ping ^a   Li, Cuiping ^a   Zhou, Jinyong ^a   Wu, Chao ^a   Zhou, Yi Hua ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; BLOOD DONOR; CHINA; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; VIRUS DETECTION; ADOLESCENT; BLOOD; CHEMISTRY; CLUSTER ANALYSIS; DNA SEQUENCE; GENE DELETION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PREVALENCE; SEQUENCE HOMOLOGY; VIROLOGY;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; BLOOD DONORS; CHINA; CLUSTER ANALYSIS; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PHYLOGENY; POLYMERASE CHAIN REACTION; PREVALENCE; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; SEQUENCE HOMOLOGY; YOUNG ADULT;

EID: 77955688697     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-193     Document Type: Article

References (46)

1. Statements from the Taormina expert meeting on occult hepatitis B virus infection. G Raimondo JP Allain MR Brunetto MA Buendia DS Chen M Colombo A Craxi F Donato C Ferrari GB Gaeta WH Gerlich M Levrero S Locarnini T Michalak MU Mondelli JM Pawlotsky T Pollicino D Prati M Puoti D Samuel D Shouval A Smedile G Squadrito C Trepo E Villa H Will AR Zanetti F Zoulim, J Hepatol 2008 49 652 657 10.1016/j.jhep.2008.07.014 18715666
2. Hepatitis B virus transfusion risk in China: proficiency testing for the detection of hepatitis B surface antigen. R Zhang L Wang J Li, Transfusion Med 2010
3. Blood donor screening: how to decrease the risk of transfusion- transmitted hepatitis B virus? C Niederhauser B Mansouri Taleghani M Graziani M Stolz C Tinguely P Schneider, Swiss Med Wkly 2008 138 134 141 18330733
4. Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico. GM Calderon F Gonzalez-Velazquez CR Gonzalez-Bonilla B Novelo-Garza JJ Terrazas ML Martinez-Rodriguez SR Cortes-Marquez JP Blanco-Flores A Rodriguez-Rodriguez MA Del Campo R Cortes-Gomez MG Mejia-Bocanegra, Transfusion 2009 49 2200 2207 10.1111/j.1537-2995.2009.02248.x 19538543
5. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. SA Kafi-abad H Rezvan H Abolghasemi A Talebian, Transfusion 2009 49 2214 2220 10.1111/j.1537-2995.2009.02245.x 19527477
6. Hepatitis B virus infection and transfusion medicine: science and the occult. FB Hollinger, Transfusion 2008 48 1001 1026 10.1111/j.1537-2995.2008. 01701.x 18454738
7. Occult hepatitis B virus infection: a case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation. CL Giudice M Martinengo P Pietrasanta L Bocciardo C Malavasi S Rastelli M Faraci G Tripodi, Blood transfus 2008 6 46 50 18661923
8. A 2010 update on occult hepatitis B infection. G Raimondo T Pollicino L Romano AR Zanetti, Pathol Biol 2010 58 254 257 10.1016/j.patbio.2010.02.003 20303674
9. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. X Liang S Bi W Yang L Wang G Cui F Cui Y Zhang J Liu X Gong Y Chen F Wang H Zheng F Wang J Guo Z Jia J Ma H Wang H Luo L Li S Jin SC Hadler Y Wang, Vaccine 2009 27 6550 6557 10.1016/j.vaccine. 2009.08.048 19729084
10. Vaccination against hepatitis B: the Chinese experience. YH Zhou C Wu H Zhuang, Chin Med J (Engl) 2009 122 98 102 19187625
11. Seroprevalence of hepatitis B surface antigen among pregnant women in Jiangsu, China, 17 years after introduction of hepatitis B vaccine. S Zhang RT Li Y Wang Q Liu YH Zhou Y Hu, Int J Gynecol Obstet 2010 109 194 197 10.1016/j.ijgo.2010.01.002
12. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? C Brechot V Thiers D Kremsdorf B Nalpas S Pol P Paterlini-Brechot, Hepatology 2001 34 194 203 10.1053/jhep.2001.25172 11431751
13. Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. EK Zervou GN Dalekos DS Boumba EV Tsianos, Transfusion 2001 41 652 658 10.1046/j.1537-2995.2001.41050652.x 11346702
14. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. G Shang CR Seed F Wang D Nie A Farrugia, Transfusion 2007 47 529 539 10.1111/j.1537-2995.2006.01146.x 17319836
15. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. Y Fang QL Shang JY Liu D Li WZ Xu X Teng HW Zhao LJ Fu FM Zhang HX Gu, J Infect 2009 58 383 388 10.1016/j.jinf.2009.02. 013 19329189
16. Two HBV DNA+/HBsAg-blood donors identified by HBV NAT in Shenzhen, China. G Shang Y Yan B Yang C Shao F Wang Q Li CR Seed, Transfus Apher Sci 2009 41 3 7 10.1016/j.transci.2009.05.001 19487161
17. Nucleic acid amplification technology for hepatitis B virus, and its role in blood donation screening in blood banks. MS Bamaga EI Azahar AK Al-Ghamdi FQ Al-Enzi FM Farahat, Saudi Med J 2009 30 1416 1421 19882053
18. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. R Gonzalez P Torres E Castro L Barbolla D Candotti M Koppelman HL Zaaijer N Lelie JP Allain JM Echevarria, Transfusion 2009 50 221 230 10.1111/j.1537-2995.2009. 02343.x 19682332
19. Avoiding false positives with PCR. S Kwok R Higuchi, Nature 1989 339 237 238 10.1038/339237a0 2716852
20. Occult hepatitis B virus infection. G Raimondo T Pollicino I Cacciola G Squadrito, J Hepatol 2007 46 160 170 10.1016/j.jhep.2006.10.007 17112622
21. Hepatitis B - a review of the role of NAT in enhancing blood safety. N Lelie A Heaton, J Clin Virol 2006 36 Suppl 1 1 2 10.1016/S1386-6532(06)80001-6 16831686
22. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. R Offergeld D Faensen S Ritter O Hamouda, Euro Surveill 2005 10 8 11 15735310
23. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. MC Chevrier M St-Louis J Perreault B Caron C Castilloux J Laroche G Delage, Transfusion 2007 47 1794 1802 10.1111/j.1537-2995.2007.01394.x 17880603
24. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. S Owusu-Ofori J Temple F Sarkodie M Anokwa D Candotti JP Allain, Transfusion 2005 45 133 140 10.1111/j.1537-2995.2004.04279.x 15660820
25. Study about seroconversion of HBV NAT screening-positive crowd from blood donors. DW Wang TB Wang FP Liu LL Shi, Chinese Journal of Experimental and Clinical Virology 2008 22 127 129 18574536
26. HBV-DNA detection in HBsAg negative blood donors and its clinical significance. BY Chen J Shen, Chinese Journal of Nosocomiology 2007 10 1240 1241
27. A prospective study of posttransfusion hepatitis B virus infection. D Wang D Tan X Cao, Chinese Journal of Experimental and Clinical Virology 2000 14 77 79 11503032
28. Molecular, immunological and clinical properties of mutated hepatitis B viruses. C Kreutz, J Cell Mol Med 2002 6 113 143 10.1111/j.1582-4934.2002. tb00317.x 12003675
29. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. SL Laulu WL Roberts, Am J Clin Pathol 2006 125 748 751 10.1309/K5EM795VNGGFGBXX 16707377
30. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. B Weber, J Med Virol 2006 78 Suppl 1 59 65 10.1002/jmv.20610 16622880
31. Hepatitis B virus genetic diversity and its impact on diagnostic assays. FB Hollinger, J Viral Hepat 2007 14 Suppl 1 11 15 10.1111/j.1365-2893.2007. 00910.x
32. Clinical impact of occult HBV infections. I Chemin C Trepo, J Clin Virol 2005 34 Suppl 1 15 21 10.1016/S1386-6532(05)80005-8 16461218
33. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. WH Gerlich D Glebe CG Schuttler, J Viral Hepat 2007 14 Suppl 1 16 21 10.1111/j.1365-2893.2007.00912.x 17958638
34. Occult hepatitis B virus infection: a covert operation. FB Hollinger G Sood, J Viral Hepat 2010 17 1 15 10.1111/j.1365-2893.2009.01245.x 20002296
35. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. A Zerbini M Pilli C Boni P Fisicaro A Penna P Di Vincenzo T Giuberti A Orlandini G Raffa T Pollicino G Raimondo C Ferrari G Missale, Gastroenterology 2008 134 1470 1481 10.1053/j.gastro.2008.02.017 18355815
36. Occult hepatitis B. M Torbenson DL Thomas, Lancet Infect Dis 2002 2 479 486 10.1016/S1473-3099(02)00345-6 12150847
37. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Y Komiya K Katayama H Yugi M Mizui H Matsukura T Tomoguri Y Miyakawa A Tabuchi J Tanaka H Yoshizawa, Transfusion 2008 48 286 294 18028278
38. Transfusion-transmitted hepatitis B virus infection. D Candotti JP Allain, J Hepatol 2009 51 798 809 10.1016/j.jhep.2009.05.020 19615780
39. Hepatitis A and B virus markers in immune serum globulin. JH Hoofnagle JG Waggoner, Gastroenterology 1980 78 259 263 6243109
40. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. S Levicnik-Stezinar U Rahne-Potokar D Candotti N Lelie JP Allain, J Hepatol 2008 48 1022 1025 10.1016/j.jhep.2008.02.016 18436328
41. A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period. S Wendel JE Levi S Biagini D Candotti JP Allain, Transfusion 2008 48 1602 1608 10.1111/j.1537-2995.2008.01723.x 18466175
42. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. BR Jackson MP Busch SL Stramer JP AuBuchon, Transfusion 2003 43 721 729 10.1046/j.1537-2995.2003.00392.x 12757522
43. Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. H Toyoda K Hayashi Y Murakami T Honda Y Katano I Nakano H Goto T Kumada J Takamatsu, J Med Virol 2004 73 195 199 10.1002/jmv.20075 15122792
44. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. CK Hui J Sun WY Au AK Lie YH Yueng HY Zhang NP Lee JL Hou R Liang GK Lau, J Hepatol 2005 42 813 819 10.1016/j.jhep.2005.01.018 15885351
45. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. SM Kim KS Lee CJ Park JY Lee KH Kim JY Park JH Lee HY Kim JY Yoo MK Jang, J Infect 2007 54 185 191 10.1016/j.jinf.2006.02.002 16564573
46. Hepatitis B virus genotypes/subgenotypes in voluntary blood donors in Makassar, South Sulawesi, Indonesia. A Utama TI Octavia R Dhenni UA Miskad I Yusuf S Tai, Virol J 2009 6 128 10.1186/1743-422X-6-128 19691824